Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Investigator-Initiated, Open-Label, Dose-Escalation Study to Evaluate the Safety, MTD, and Antitumor Activity of JIN-A02 in Combination With Amivantamab in EGFR-Mutant NSCLC Patients Following 3rd-Generation EGFR-TKI Failure

NCT07798921 is registered in ClinicalTrials.gov with Yonsei University as lead sponsor.

NCT NCT07798921
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07798921 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Investigator-Initiated, Open-Label, Dose-Escalation Study to Evaluate the Safety, MTD, and Antitumor Activity of JIN-A02 in Combination With Amivantamab in EGFR-Mutant NSCLC Patients Following 3rd-Generation EGFR-TKI Failure
Lead sponsor
Yonsei University
Phase
Phase 1
Overall status
Not yet recruiting
Start date
September 28, 2026
Completion date
December 31, 2030
Enrollment
36 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small-cell lung